In the TCGA pancreatic cancer cohort, gene alteration of TP53, KRAS, Smad4 and CDKN2A were found to be 41%, 23%, 21% and 13%, respectively (Figure 3A). This evidence concerns the gene SMAD4 and familial pancreatic carcinoma.